C4 therapeutics announces upcoming data presentations for cft8634, an orally bioavailable bidac™ degrader in development for synovial sarcoma and smarcb1-null tumors, and cft7455, an orally bioavailable monodac™ degrader in development for multiple myeloma and non-hodgkin's lymphoma

Cft8634 phase 1 dose escalation data to be presented at the connective tissue oncology society annual meeting on november 2, 2023

CCCC Ratings Summary

CCCC Quant Ranking